Akademik Veri Yönetim Sistemi
JOURNAL OF CURRENT HEMATOLOGY&ONCOLOGY RESEARCH, cilt.1, sa.3, ss.54-58, 2023 (Hakemli Dergi)
Aims: The activation of the Wnt/ β-catenin signaling pathway has been demonstrated to play a crucial role in the development
of myeloid neoplasms. In addition to CD34, which has been used until now in the diagnosis and staging of clonal hematopoietic
diseases, Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN), CD117, which has found its place in
hematopoietic diseases, also provides significant benefits in these respects. In this study, we evaluated the immunohistochemical
presence and utility of β-catenin in blasts relative to other markers, as the inhibition of β-catenin activity may be an attractive
therapeutic approach
Methods: By retrospectively analyzing bone marrow samples with β-catenin immune marker, we determined the staining
rates, intensities, and patterns of 30 MDS, 29 MPN cases and 30 normal bone marrow controls, in comparison to the efficacy of
the the well-known CD34 and CD117. We statistically interpreted the correlation between them.
Results: Based on the findings, β-catenin, which has recently been used in hematopoietic diseases and is said to have a high
efficacy in acute myeloid leukemia (AML) cases, was not immunohistochemically detectable in our study. As expected, CD34
and CD117 immun markers exhibited significant blast staining. MPN cases were more prone to staining with CD117.
Conclusion: CD34 continues to be the most reliable marker for identifying blasts for diagnosing and grading bone marrow
neoplasms while CD117 may have a supportive role in this process. Further investigation is required to ascertain the true
effectiveness of β-catenin, a molecule that has demonstrated encouraging potential in the context of AML.